cangrelor
Sign in to saveAlso known as AR-C69931MX, ARL69931, Kengreal®, [dichloro-[[[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]methyl]phosphonic acid
Cangrelor, sold under the brand name Kengreal among others, is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation.
Key facts
- Drug.image
- Cangrelor structure.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 300
- Drug.tradename
- Kengreal, Kengrexal, others
- Drug.DailyMedID
- Cangrelor
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- B01
- Drug.ATC_suffix
- AC25
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- 100% (IV)
- Drug.protein_bound
- ~97–98%.
- Drug.metabolism
- Rapid deactivation in the circulation (independent of CYP system)
- Drug.elimination_half life
- ~3–6 minutes
- Drug.excretion
- Kidney (58%), Bile duct (35%)
- Drug.index2_label
- as salt
- Drug.IUPHAR_ligand
- 1776
via Wikipedia infobox
Research
852 papers- Cangrelor in clinical use.Future cardiology · 2020
- Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.Journal of the American Heart Association · 2021
- Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.JAMA · 2012
- Cangrelor for the treatment of patients with Arterial Thrombosis.Expert opinion on pharmacotherapy · 2018
- The role of cangrelor in acute and high-risk PCI settings.European heart journal. Cardiovascular pharmacotherapy · 2025
via PubMed
~5 min read
Encyclopedic overview
7 sectionsContents
- Medical use
- Adverse effects
- Pharmacology
- Chemistry
- Synthesis
- Research
- References
Cangrelor, sold under the brand name Kengreal among others, is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation.
It is authorized as a generic medication.
Excerpted from Wikipedia’s “cangrelor” article, available under the CC BY-SA 4.0 licence.